Eli Lilly and Company (NYSE: LLY) will provide donations of medicines and money for victims of the catastrophic earthquake in Haiti on January 12. Lilly has initially pledged $250,000 in direct cash contributions.

Working directly with humanitarian partners to help address the growing health care crisis, Abbott (NYSE: ABT) is expanding its support for relief efforts in Haiti. The company will provide $2.5 million in grant funding and donations of critical pharmaceutical and nutritional products to humanitarian aid organizations.

Through its local organizations in countries throughout the region, Novartis is providing the equivalent of over USD 2.5 million in immediate emergency aid for victims of the recent earthquake in Haiti. The support includes both direct financial aid to relief agencies working in Haiti as well as donations of essential medicines, including antibiotic and pain relieving drugs.

Amgen (Nasdaq: AMGN) announced that the company will donate $2 million to Haiti relief efforts. Amgen staff are being encouraged to be generous and that effort should also generate meaningful additional support.

Abbott (NYSE: ABT) and its philanthropic foundation the Abbott Fund have committed to provide $1 million in initial humanitarian aid in response to the earthquake in Haiti. This support includes grant funding and donations of critical pharmaceutical and nutritional products to strengthen the ability of humanitarian aid organizations to respond to immediate health needs in Haiti.

Novo Nordisk has initiated its first phase 1 clinical trial with a long-acting oral GLP-1 analogue (NN9924). This milestone releases a 2 million dollar payment to Emisphere Technologies, Inc., whose proprietary Eligen® Technology is used in the formulation of NN9924.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States (US) Food and Drug Administration (FDA) approved ACTEMRA (tocilizumab, RoACTEMRA in the European Union) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.